DexCom DXCM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 61.5%+1.4pp | 60.1%+1.1pp | 59%+0.2pp | 58.8%-0.7pp | 59.4%-1.0pp | |
| Operating margin | 21.4%+1.9pp | 19.6%+2.3pp | 17.2%+1.2pp | 16%+0.7pp | 15.3%+0.4pp | |
| Net margin | 19.3%+1.4pp | 17.9%+2.0pp | 16%+2.7pp | 13.3%+0.4pp | 12.9%-1.4pp | |
| EBITDA margin | 26.8%+1.9pp | 25%+2.3pp | 22.6%+1.2pp | 21.5%+0.8pp | 20.7%+0.4pp | |
| Free cash flow margin | 29.7%+6.6pp | 23.1%-0.4pp | 23.5%+10.2pp | 13.3%-0.6pp | 13.9%-1.8pp | |
| Returns | ||||||
| Return on equity | 35.6%+1.1pp | 34.5%+3.9pp | 30.6%+7.8pp | 22.8%-0.9pp | 23.7%-3.9pp | |
| Return on assets | 13.9%+0.9pp | 13%+2.6pp | 10.4%+2.3pp | 8.1%0.0pp | 8.1%-1.0pp | |
| Return on invested capital | 45.9%+7.3pp | 38.6%-7.7pp | 46.3%+14.9pp | 31.3%+0.9pp | 30.4%+1.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×+0.1× | 0.7×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Inventory turnover | 3×-0.2× | 3.2×+0.1× | 3.1×0.0× | 3.1×+0.1× | 3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 1.9×+0.1× | 1.9×+0.3× | 1.6×0.0× | 1.5×0.0× | 1.5×0.0× | |
| Quick ratio | 1.6×0.0× | 1.6×+0.2× | 1.4×0.0× | 1.3×0.0× | 1.3×0.0× | |
| Cash ratio | 0.5×+0.1× | 0.4×-0.1× | 0.6×+0.2× | 0.4×+0.1× | 0.3×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0.1×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -0.8×-0.1× | -0.7×+1.0× | -1.7×-0.6× | -1.1×-0.2× | -0.9×-0.3× | |
| Per Share | ||||||
| Book value per share | $7.51+10.9% | $6.77+1.2% | $6.69+6.2% | $6.30+13.3% | $5.56+9.2% | |
| Valuation | ||||||
| Market capitalization | $24.17B-6.6% | $25.89B-1.9% | $26.39B-23.1% | $34.34B+28.2% | $26.78B-11.8% | |
| Enterprise value | $23.19B-7.7% | $25.12B+1.8% | $24.68B-25.9% | $33.31B+28.1% | $26.01B-13.1% | |
| Price / earnings | 26×-5.0× | 31×-5.7× | 36.6×-23.5× | 60.1×+10.1× | 50×-2.7× | |
| Price / sales | 5×-0.5× | 5.6×-0.3× | 5.8×-2.1× | 8×+1.5× | 6.5×-1.1× | |
| Price / book | 8.2×-1.3× | 9.4×-0.3× | 9.7×-3.7× | 13.3×+1.5× | 11.8×-2.6× | |
| EV / EBITDA | 17.9×-3.6× | 21.6×-2.6× | 24.1×-11.9× | 36.1×+5.8× | 30.3×-6.3× | |
| EV / sales | 4.8×-0.6× | 5.4×-0.1× | 5.5×-2.3× | 7.7×+1.5× | 6.3×-1.1× | |
| Free cash flow yield | 5.9%+1.8pp | 4.2%+0.1pp | 4%+2.4pp | 1.7%-0.5pp | 2.1%+0.1pp | |
| Earnings yield | 3.8%+0.6pp | 3.2%+0.5pp | 2.7%+1.1pp | 1.7%-0.3pp | 2%+0.1pp | |
| PEG ratio | 0.4×-0.3× | 0.7×-5.6× | 6.2×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are DexCom's profit margins?
- DexCom (DXCM) runs a 61.5% gross margin and a 21.4% operating margin, with a 19.3% net margin.
- Where do DexCom's ratios come from?
- Every ratio is computed from DexCom's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
